New treatments in type 2 diabetes: a focus on the incretin-based therapies
- 1 March 2009
- journal article
- review article
- Published by Wiley in Clinical Endocrinology
- Vol. 70 (3), 343-353
- https://doi.org/10.1111/j.1365-2265.2008.03396.x
Abstract
The demonstration that the incretin hormone glucagon-like peptide 1 can improve glycaemic control in patients with type 2 diabetes has led to the rapid development during the last decade of promising new classes of agent for the management of type 2 diabetes. These agents possess a range of physiological effects that are associated with improved glycaemic control in diabetes including stimulation of glucose-dependent insulin secretion, suppression of glucagon secretion, slowing of gastric emptying, and reduction of food intake. In addition, preclinical studies suggest that incretin-based therapies may improve beta-cell function via enhancement of beta-cell mass and induction of genes important for differentiated beta-cell function. Exenatide, and the dipeptidyl peptidase-4 inhibitors, sitagliptin and vildagliptin are already approved, and liraglutide is currently completing Phase 3 trials. As these agents and standard oral therapies for type 2 diabetes lower glucose levels through different, but potentially complementary mechanisms, their use in combination should provide effective, potentially additive, glycaemic control. The incretin-based therapies also offer other advantages such as weight loss with exenatide and liraglutide, a reduced risk of hypoglycaemia, and as suggested by preclinical studies, a potential beta-cell preserving effect. Long-term outcome and safety data are not available for these agents, but they appear generally well-tolerated in comparison with existing therapies for type 2 diabetes. The multiple underlying glucose-lowering actions of the incretin-based therapies, as well as a lack of weight gain or even weight loss, make these important new additions to available antidiabetic agents expanding the treatment options available for patients.Keywords
This publication has 95 references indexed in Scilit:
- Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal careDiabetic Medicine, 2006
- HOMA-Estimated Insulin Resistance Is an Independent Predictor of Cardiovascular Disease in Type 2 Diabetic SubjectsDiabetes Care, 2002
- Pathophysiology of Type 2 Diabetes Mellitus in Children and AdolescentsTreatments in Endocrinology, 2002
- Insulin Resistance and Insulin Secretory Dysfunction Are Independent Predictors of Worsening of Glucose Tolerance During Each Stage of Type 2 Diabetes DevelopmentDiabetes Care, 2001
- The importance of the β-cell in the pathogenesis of type 2 diabetes mellitusAmerican Journal Of Medicine, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitusBMJ, 1997
- U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive DiseaseDiabetes, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- The Effect of Long-Term Intensified Insulin Treatment on the Development of Microvascular Complications of Diabetes MellitusNew England Journal of Medicine, 1993